Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 18, 2017 08:00 ET | Source: CytomX Therapeutics Inc.

CytomX Therapeutics Added to NASDAQ Biotechnology Index

SOUTH SAN FRANCISCO, Calif., Dec. 18, 2017 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a clinical-stage biopharmaceutical company developing investigational Probody™ therapeutics...
November 28, 2017 08:30 ET | Source: CytomX Therapeutics Inc.

CytomX Therapeutics Announces FDA Acceptance of Investigational New Drug Application for CTLA-4 Probody Therapeutic

Goal is a safer, more effective version of Yervoy® Triggers $10 Million Milestone Payment to CytomX from Bristol Myers Squibb NEW YORK and SOUTH SAN FRANCISCO, Calif., Nov. 28, 2017 (GLOBE...
November 01, 2017 16:05 ET | Source: CytomX Therapeutics Inc.

CytomX to Present at the Jefferies 2017 London Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Nov. 01, 2017 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a biopharmaceutical company developing investigational Probody™ therapeutics for the treatment...
October 26, 2017 16:25 ET | Source: CytomX Therapeutics Inc.

CytomX Therapeutics to Announce Third Quarter 2017 Financial Results

SOUTH SAN FRANCISCO, Calif., Oct. 26, 2017 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a biopharmaceutical company developing investigational Probody™ therapeutics for the treatment...
October 24, 2017 16:05 ET | Source: CytomX Therapeutics Inc.

CytomX Therapeutics Appoints Charles S. Fuchs, M.D., MPH to Board of Directors

SAN FRANCISCO, Oct. 24, 2017 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a biopharmaceutical company developing investigational Probody™ therapeutics for the treatment of cancer,...
October 16, 2017 13:00 ET | Source: CytomX Therapeutics Inc.

CytomX Announces Upcoming Poster Presentations at AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics International Conference

SOUTH SAN FRANCISCO, Calif., Oct. 16, 2017 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a biopharmaceutical company developing investigational Probody™ therapeutics for the treatment...
September 13, 2017 16:05 ET | Source: CytomX Therapeutics Inc.

CytomX to Present at the Cantor Fitzgerald Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Sept. 13, 2017 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a biopharmaceutical company developing investigational Probody™ therapeutics for the...
September 08, 2017 16:38 ET | Source: CytomX Therapeutics Inc.

CytomX Announces Upcoming Trials in Progress Poster Presentations at European Society for Medical Oncology Annual Meeting

SOUTH SAN FRANCISCO, Calif., Sept. 08, 2017 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a biopharmaceutical company developing investigational Probody™ therapeutics for the...
August 10, 2017 16:05 ET | Source: CytomX Therapeutics Inc.

CytomX to Present at the 2017 Wedbush PacGrow Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Aug. 10, 2017 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a biopharmaceutical company developing investigational Probody™ therapeutics for the treatment...
August 07, 2017 16:05 ET | Source: CytomX Therapeutics Inc.

CytomX Announces Second Quarter 2017 Financial Results and Mid-Year Update Webcast Conference Call

Strong Pipeline Momentum Continues Initiated Combination Arms in Phase 1/2 PROCLAIM-CX-072 Study Initiated Phase 1/2 PROCLAIM-CX-2009 Study SOUTH SAN FRANCISCO, Calif., Aug. 07, 2017 (GLOBE...